Darapladib , as compared with placebo , reduced the rate of major coronary events ( @ % vs. @ % ; hazard ratio , @ ; @ % CI , @ to @ ; P = @ ) and total coronary events ( @ % vs. @ % ; hazard ratio , @ ; @ % CI , @ to @ ; P = @ ) .